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Abstract
Meningiomas contain highly variable levels of infiltrating tissue macrophages (TiMa) and other immune cells. In this study
we investigated the potential association between the number and immunophenotype of inflammatory and other immune
cells infiltrating the tumor as evaluated by multiparameter flow cytometry, and the clinico-biological, cytogenetic and gene
expression profile (GEP) of 75 meningioma patients. Overall, our results showed a close association between the amount
and cellular composition of the inflammatory and other immune cell infiltrates and the cytogenetic profile of the tumors.
Notably, tumors with isolated monosomy 22/del(22q) showed greater numbers of TiMa, NK cells and (recently)-activated
CD69+ lymphocytes versus meningiomas with diploid and complex karyotypes. In addition, in the former cytogenetic
subgroup of meningiomas, tumor-infiltrating TiMa also showed a more activated and functionally mature phenotype, as
reflected by a greater fraction of CD69+, CD63+, CD16+ and CD33+ cells. GEP at the mRNA level showed a unique GEP among
meningiomas with an isolated monosomy 22/del(22q) versus all other cases, which consisted of increased expression of
genes involved in inflammatory/immune response, associated with an M1 TiMa phenotype. Altogether, these results
suggest that loss of expression of specific genes coded in chromosome 22 (e.g. MIF) is closely associated with an increased
homing and potentially also anti-tumoral effect of TiMa, which could contribute to explain the better outcome of this
specific good-prognosis cytogenetic subgroup of meningiomas.
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Introduction
Meningiomas are usually considered to be benign central
nervous system tumors, on both histopathological [1] and clinical
[2] grounds. Despite this, a significant fraction of all meningiomas
will eventually relapse with a negative impact in patient outcome
[2]. In recent years, tumor cytogenetics has emerged as the most
relevant prognostic factor, together with tumor histopathology/
grade and patient age and sex [3,4]. Whereas cases displaying
complex karyotypes, particularly monosomy 14 in association with
del(1p), display a dismal outcome [5], tumors with isolated
monosomy 22/del(22q) show a particularly good prognosis, the
molecular basis of such clinical behavior remaining to be fully
understood [3,5,6].
Although tumor histopathology and tumor behavior are, at least
in part, related to tumor cytogenetics [2,7], they might also be
influenced by specific changes in the tumor microenvironment
[8,9]. In this regard, we have recently reported the existence of
variable levels of infiltration of meningiomas by inflammatory and
other immune cells [10]. CD45+ inflammatory cells that infiltrated
meningiomas mainly included tissue macrophages (TiMa) with an
HLA-DR+CD14+CD45+CD68+CD162/+CD332/+ phenotype
and a high phagocytic/endocytic activity, together with a smaller
population of cytotoxic lymphocytes, mostly CD8+ T cells and
NK-cells [10]. Previous studies in other tumor types such as
melanoma and colorectal cancer [11,12], have shown that
infiltration by immune cells is associated with specific features of
the disease, including a better outcome. In meningiomas, previous
reports indicate that the type and level of infiltrating inflammatory
cells are both associated with the histopathological features of the
tumor [9,10,13]. However, so far no study has investigated the
potential association between tumor infiltrates of inflammatory
and other immune cells, and other features of the disease including
cytogenetics.
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In this study we investigated the association between the cellular
composition and protein expression profiles of meningiomas as
analyzed by multiparameter flow cytometry, and the clinico-
biological, genetic and mRNA gene expression profiling features of
the disease. Our results indicate that the presence of inflammatory
infiltrates of antigen presenting cells (TiMa) and lymphocytes is
clearly associated with tumors displaying isolated monosomy 22/
del(22q), which could contribute to explain the better outcome of
this specific cytogenetic subgroup of meningiomas.
Materials and Methods
Patients and samples
Overall, 78 tumor samples from 75 patients (20 males and 55
females; mean age of 60614 years; range: 23 to 84 years)
diagnosed with meningioma at the Neurosurgery Service of the
University Hospital of Salamanca (Salamanca, Spain), were
analyzed in this study. According to the WHO criteria [2] 64
(82%) tumors were benign/grade I meningiomas, 11 (14%) were
atypical/grade II tumors and 3 (4%) were grade III meningiomas.
Fresh tumor tissue samples and ethylenediamine tetraacetic acid
(EDTA)-anticoagulated peripheral blood (PB) samples were
obtained in parallel from each patient, after written informed
consent was given according to the guidelines of the local Ethics
Committee. Tumor tissue samples were frozen in liquid nitrogen
immediately after surgical removal, whereas PB samples were
immediately processed as described below.
Brain edema was found in 37/75 (49%) patients. According to
its extension, it was evaluated as light (smaller or equal to the
volume of the tumor) in 11 cases (15%), moderate (doubling the
volume of the tumor) in 16 cases (21%) and severe (more than
twice the volume of the tumor) in 10 cases (13%). The most
relevant clinical, histopathological and cytogenetic features of the
tumors analyzed by flow cytometry and gene expression profiling
are summarized in Table S1. The study was approved by the local
Ethics Committee and Institutional Review Board of the
University Hospital of Salamanca. At the moment of closing this
study 6/75 patients had relapsed (8%) after a median follow-up of
48 months (range: 1 to 238 months). From these relapsed cases, all
except one underwent complete tumor resection and three were
submitted to radiotherapy; 4 were benign/grade I meningiomas, 1
a grade II tumor and the other case was a grade III meningioma.
Multiparameter flow cytometry (MFC)
immunophenotyping
For the immunophenotypic flow cytometry analyses, single
tumor cell suspensions were obtained from 51 freshly-frozen
meningioma samples (46 WHO grade I, 3 WHO grade II and 2
WHO grade III tumors), through conventional mechanical
disaggregation procedures [14,15] in phosphate buffered saline
(PBS) containing 10% fetal bovine serum (FBS; Invitrogen,
Carlsbad, CA, USA), 1% bovine serum albumin (BSA) (Sigma,
St. Louis, MO, USA) and 2 mM EDTA (Merck, Darmstadt,
Germany). Thawed meningioma cells were stained for 30 min at
4uC in the darkness with the following monoclonal antibodies
(mAb): CD2- fluorescein isothiocyanate (FITC), CD13- phycoer-
ythrin (PE), CD14-PE, CD33-PE, CD58-PE, CD69-PE, HER2/
neu-PE and HLA-DR-FITC, purchased from Becton/Dickinson
(BD) Biosciences (BDB, San Jose, CA, USA); CD22-FITC, CD37-
FITC, CD53-PE, CD55-FITC, CD81-PE and CD99-PE from BD
Pharmigen (San Diego, CA, USA); CD9-FITC, CD16-FITC,
CD63-FITC and HLA-I-FITC purchased from Beckman/Coulter
(Fullerton, CA, USA); CD44-PE and CD59-FITC obtained from
Immunostep SL (Salamanca, Spain); Bcl2-FITC and CD45-
Pacific Blue (PacB) purchased from DAKO (Glostrup, Denmark);
CD38-FITC from Cytognos SL (Salamanca, Spain), and; CD68-
FITC obtained from An der Grub (ADG, Vienna, Austria). For
reproducible identification of all nucleated cells and leukocytes
present in each sample, staining for the above listed mAb was
systematically done in 4-colour stainings in which CD45-PacB and
DRAQ5 (Cytognos SL) were combined with the above listed
FITC and PE-conjugated mAb reagents. Absence of blood
infiltration at single cell suspensions was confirmed based on the
lack of CD16+CD45+ neutrophils in the samples. For cytoplasmic
(Cy) markers (Cybcl2 and CyCD68), cells were permeabilized (1 h
at 220uC) prior to intracellular staining, as described elsewhere
[16]. For further lymphocyte subset analysis, an additional 5-color
staining – CD45 Pacific Orange (PacO; Invitrogen), CD3-PacB
(BD), CD8-FITC (BD), CD19-FITC (BD) and CD56-PE (Cytog-
nos SL) -, was used. For all tubes, staining with DRAQ5 was
performed 5 min prior to the measurement in the flow cytometer,
as previously described [17]. To assess control baseline autofluo-
rescence levels, an aliquot of each tumor sample stained only for
DRAQ5 was measured in parallel.
Data acquisition was performed for $16105 cells per antibody
combination in a FACSCanto II flow cytometer (BD), using the
FACSDivaTM 6.0 software (BDB). The INFINICYT software
program (Cytognos SL) was used for data analysis, aimed at
determining both the percentage of positive cells and the amount
of protein expressed per cell – mean fluorescence intensity (MFI) –
for each individual marker analyzed within each cell population of
interest.
Interphase Fluorescence in situ hybridization (iFISH)
For all freshly-frozen tumor samples obtained during surgery,
iFISH analysis was performed for a panel of 12 probes specific for
chromosomes 1p36/1q25, CEP 7/10, 9p34/22q11.2 (LSI BCR/
ABL), 14q32.3/18q21 (LSI IgH/BCL2), 15q22/17q21 (LSI
PML/RAR-a) and CEP X/Y (Vysis Inc., Downers Grove, IL)
according to previously described double-staining techniques [7].
Gene expression profiling (GEP)
In a subset of 40 meningioma samples (28 WHO grade I, 11
WHO grade II and 1 WHO grade III tumors), GEP was analyzed
with the Human Genome 133A Affymetrix array (Affymetrix Inc,
Santa Clara, CA, USA). After thawing, tumors were homogenized
with a Potter-’S’-Elvehjem homogenizer (Uniform, Jencons, UK)
and total RNA was isolated using TRIzol (Invitrogen) and the
RNeasy Mini Kit (QIAGEN, Valencia, CA, USA). The integrity/
purity of the purified RNA was determined using a microfluidic
electrophoretic system (Agilent 2100 Bioanalyzer; Agilent Tech-
nologies, Palo Alto, CA, USA). Then, GEPs were analyzed
according to the manufacturer’s instructions, using the one-cycle
cDNA synthesis kit and the Poly-A RNA gene chip control kit
(Affymetrix Inc.), as reported elsewhere [6,18]. Data files
containing data about the expression levels for the 40 tumors
were normalized – Robust microarray normalization (RMA) – and
analyzed using the R (version 2.7.0; http://www.r-project.org) and
Bioconductor (http://www.bioconductor.org) software tools. The
microarray dataset is available in the Gene Expression Omnibus
(GEO) public data repository (GSE43290 access code). Differen-
tially expressed genes between samples from the different
cytogenetic subgroups of meningiomas were identified using a
supervised two-class unpaired Significance Analysis of Microarray
(SAM) [19], based on a combined cutoff with a false discovery rate
of ,0.05 (T-test). Further investigation of the altered pathways
was performed using the Ingenuity Pathway Analysis (IPA)
software (Ingenuity Systems Inc., Redwood City, CA, USA).
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Through the IPA software the specific cell functions associated
with those genes under- or over-expressed in each specific
cytogenetic subgroup of meningiomas were first investigated. In
a second step, the IPA software was used for a more detailed
analysis of those signaling pathways involving genes which were
under- and/or over-expressed among meningiomas with isolated
monosomy 22/del(22q) vs other meningioma tumors. For this
purpose, those genes being associated with the highest scored ‘Bio
Functions’ for this specific cytogenetic subgroup of meningiomas
were selected (e.g. cell growth and proliferation of immune cells;
hematological system development and function; immune cell
trafficking; cell-to-cell signaling and interaction of immune cells;
inflammatory response). In the following step, those genes showing
more ‘Direct Relationships’ as well as those associated with
‘Antigen Presenting Cell functions’ were selected for the ‘Path
Designer’ tool of the IPA software.
Immunohistochemical analyses
In a representative subgroup of samples (n = 12), immunostain-
ing of macrophages was performed with the anti-CD68 antibody
to confirm tissue localization of these cells. For this purpose, 3mm-
thick tissue sections were cut from paraffin-embedded blocks,
deparaffinized, and stained in a Leica-BOND-III automated
immunostainer (Leica Biosystems, Wetzlar, Germany) using the
Bond Polymer Refine Detection kit (Leica Biosystems), according
to the manufacturer’s instructions. Briefly, after rehydrated,
antigen retrieval was achieved with citrate buffer (pH 6.0) and
endogenous peroxidase was blocked by incubation in 3%
hydrogen peroxide. Sections were then incubated with an anti-
CD68 mAb (clone KP1, dilution 1:50; Master Diagno´stica,
Granada, Spain), for 20 minutes, followed by the rabbit anti-
mouse Post Primary, the polymeric horseradish peroxidase (HRP)
and its 3,39-diaminobenzidine (DAB) substrate as the final
chromogen. All immunostained sections were lightly counter-
stained with hematoxylin. Analysis was performed in an Olympus
BX5 microscope equipped with a 100x oil objective (Olympus,
Melville, NY, USA).
Statistical methods and hierarchical clustering
For each continuous variable analyzed, its median, mean and
standard deviation (SD) values, as well as range and both the 25th
and 75th and the 10th and 90th percentiles, were calculated; for
categorical variables, frequencies were reported. Statistical signif-
icance was determined through the non-parametric Kruskal-
Wallis and Mann-Whitney U tests (for continuous variables) or the
Pearsons Chi-square test (for categorical variables); the Spear-
man’s correlation was used to explore the degree of correlation
between different variables (SPSS 15.0 software, SPSS, Chicago,
IL, USA). The Kaplan-Meier method was used to construct
relapse-free survival (RFS) curves, and the log-rank test was
applied to compare RFS curves. P-values,0.05 (with a FDR
correction for multiple comparisons of ,10%), were considered to
be associated with statistical significance.
The most discriminant cut-off value for low vs high tumor
infiltration by inflammatory cells was calculated using receiver
operating characteristic (ROC) curve analysis.
For unsupervised clustering analyses, normalization of the
datasets was performed for each parameter by calculating the ratio
between the value obtained for each sample and the median of all
samples analyzed. A logarithmic (base 2) transformation was
applied to the ratio values, and the log2 ratios were then used for
hierarchical clustering analyses (Cluster 3.0 and Tree View
software; Stanford University, Stanford, CA, USA). Unsupervised
hierarchical cluster analyses were performed using the Pearson
correlation and the average linkage clustering method. Principal
component (PC) analysis (PCA) was performed using the Multi-
Experiment Viewer Software (MeV v4.8, TM4 Microarray
Software Suite).
Results
Inflammatory infiltrates in meningioma samples and its
association with disease features
As previously described [10], all meningioma samples showed
infiltration by inflammatory and other immune cells by flow
cytometry, although their percentage was highly variable among
the distinct tumors. In order to investigate the potential association
between the amount of the inflammatory infiltrate by flow
cytometry and other features of the disease, patients were divided
into cases with low (,23%) and high ($23%) percentage of the
most represented inflammatory cells (CD14+ HLA-DR+ CD45+
TiMa) in the tumor infiltrates, based on ROC curve analysis –
area under the curve (AUC) of 90% (p,0.001) for the selected
cutoff (23% of TiMa) -. Immunohistochemical expression of CD68
was detected in the cytoplasm of morphologically heterogeneous
mononuclear cells scattered within the tumor tissue, as single cells
or groups of cells, only occasionally localized in perivascular areas
(Figure 1). On the basis of their immunophenotype, morphology
and localization, these cells were identified as mainly correspond-
ing to macrophages infiltrating the tumor.
Comparison of patients with low (,23% TiMa) vs high ($23%
TiMa) levels of tumor infiltration by inflammatory cells (Table 1)
showed a clearly different distribution of tumors according to their
iFISH cytogenetic profiles (p = 0.001); conversely, both groups of
patients showed a similar distribution according to age, sex, tumor
localization, histopathological subtypes and WHO tumor grade,
together with a similar degree of brain edema and frequency of
relapses (p.0.05). From the cytogenetic point of view, a highly
significant association was found between meningiomas carrying
isolated monosomy 22/del(22q) alone and high levels of infiltra-
tion by TiMa, most tumors carrying isolated monosomy 22/
del(22q) (14/17 cases, 82%) showing infiltration by $23% TiMa
(Table 1).
Of note, whereas cases with either a diploid karyotype or
isolated monosomy 22/del(22q) tumors showed a longer RFS than
meningioma patients carrying complex karyotypes (p = 0.01), the
level of tumor infiltration by TiMa on itself did not show a
significant impact on patient outcome (p.0.05).
The immunophenotypic profile of inflammatory cells in
tumor infiltrates varies according to tumor cytogenetics
Based on the iFISH analyses for chromosomes 1p36/1q25, 7,
9p34, 10, 14q32.3, 15q22, 17q21, 18q21, 22q11.2, X and Y,
patients were classified according to tumor cytogenetics as having
a diploid karyotype – 29/75 cases (39%) -, isolated monosomy 22/
del(22q) – 26/75 cases (35%) – and a complex iFISH karyotype
with losses and/or gains of two or more chromosomes – 19/75
cases (25%); the remaining case showed an isolated loss of
chromosome 1p.
A more detailed analysis of the immunophenotypic features of
TiMa from meningioma samples with distinct karyotypes showed
that cases with isolated monosomy 22/del(22q) not only displayed
significant increased levels of infiltration by TiMa versus
meningiomas with both diploid (p,0.001, Figure 2B) and complex
karyotypes (p = 0.02, Figure 2B), but they also showed a distinct
immunophenotypic profile for such TiMa (Figure 3). Accordingly,
TiMa from meningiomas with isolated monosomy 22/del(22q)
showed increased expression levels of several activation-associated
Inflammatory Infiltrates in Meningiomas
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Figure 1. Immunohistochemical staining of meningioma tissues with the anti-CD68 antibody. CD68-positive cells detected within the
tumor parenchyma showed reactivity in their cytoplasm and a mononuclear cell appearance, compatible with macrophages infiltrating the tumor. An
overview of the whole tissue from a representative case (original magnification,6400) (panel A) and a higher amplification of areas containing CD68-
positive cells (original magnification,61000) (panel B), are displayed.
doi:10.1371/journal.pone.0074798.g001
Table 1. Clinical, biological and cytogenetic characteristics of meningioma patients with high ($23%) versus low (,23%) degree
of tumor infiltration by tissue macrophages (TiMa; n = 51).
Total cases
(n =51)
% of TiMa ,23
(n=29)
% of TiMa $23
(n =22) p-value
Age (years) 58613 59614 56612 NS
Gender Female 36 (71%) 19 (66%) 17 (77%) NS
Male 15 (29%) 10 (44%) 5 (23%)
Tumor localization Convexity 17 (33%) 7 (24%) 10 (45%) NS
Cranial base 14 (27%) 11 (38%) 3 (14%)
Convexity/Parasagittal 8 (16%) 4 (13%) 4 (18%)
Parasagittal 6 (12%) 3 (10%) 3 (14%)
Tentorial 2 (4%) 2 (7%) 0 (0%)
Intraosseous 1 (2%) 1 (4%) 0 (0%)
Spinal 3 (6%) 1 (4%) 2 (9%)
Tumor grade Grade I 46 (90%) 25 (86%) 21 (95%) NS
Grade II 3 (6%) 2 (7%) 1 (5%)
Grade III 2 (4%) 2 (7%) 0 (0%)
Tumor histopathology Meningothelial 14 (27%) 9 (31%) 5 (23%) NS
Transitional 16 (31%) 10 (35%) 6 (27%)
Psammomatous 7 (14%) 3 (10%) 4 (18%)
Fibroblastic 7 (14%) 1 (3%) 6 (27%)
Other * 7 (14%) 6 (21%) 1 (5%)
iFISH karyotype Diploid 17 (33%) 14 (48%) 3 (14%) 0.001
Monosomy 22/del(22q) 17 (33%) 3 (10%) 14 (63%)
Complex 16 (32%) 11 (38%) 5 (23%)
del(1p) 1 (2%) 1 (4%) 0 (0%)
Edema No/light 30 (59%) 14 (48%) 16 (73%) NS
Moderate/severe 21 (41%) 15 (52%) 6 (27%)
Relapses Yes 4 (8%) 1 (4%) 3 (14%) NS
No 47 (92%) 28 (96%) 19 (86%)
NS, statistically no significant differences observed (p.0.05).
*Includes one angiomatous, one secretory, one rhabdoid, one papillary and three atypical meningioma cases.
doi:10.1371/journal.pone.0074798.t001
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markers with higher percentages of CD69+ (p#0.009 vs diploid
and complex tumors; Figure 3A) and CD63+ TiMa (p = 0.006 vs
diploid cases; Figure 3B). In addition, TiMa from meningiomas
with isolated monosomy 22/del(22q) also displayed a higher
percentage of CD16+ cells vs tumors with complex karyotypes
(p = 0.004; Figure 3C); despite not statistically significant, higher
percentages of CD33+ cells were also associated with 222/22q2
cases (Figure 3D). In turn, they showed intermediate levels of
expression of both the CD44 and CD9 adhesion molecules,
between those of diploid and complex karyotype tumors (p,0.05;
Figures 3E and 3F).
Conversely, no significant differences (p.0.05) were found
regarding the amount of lymphocytes infiltrating the tumor
(Figure 2C), neither their major subsets (Figure 4), except for
higher numbers of NK-cells in cases with isolated monosomy 22/
del(22q) vs diploid tumors (p = 0.03; Figure 4E). Interestingly, this
was also associated with an increased percentage of CD69+
lymphocytes among meningiomas with isolated monosomy 22/
del(22q) vs both cases with diploid and complex iFISH karyotypes
(p,0.05; Figure 4D).
In line with the above observations, unsupervised hierarchical
clustering analysis, based on the number and immunophenotypic
features of the inflammatory tumor infiltrates of each meningioma,
showed two major clusters of tumors (Figure 5A): one group
(group A) included the great majority of patients (13/17, 76%)
with meningiomas carrying isolated monosomy 22/del(22q),
whereas the other group (group B) comprised most patients with
a diploid (14/17, 82%) or complex karyotype (10/16, 63%). As
expected, group A cases were characterized by both higher levels
of infiltration by TiMa and lymphocytes, and greater percentages
of CD69+ activated TiMa and lymphocytes. Additionally,
principal component analysis based on the percentages of
lymphocytes and TiMa infiltrating meningioma samples and their
immunophenotypic features, also identified a homogeneous group
of samples (n = 13/51) which included almost only cases with
isolated monosomy 22/del(22q) (11/13, 85%; Figure 5B).
Association between the gene expression profile and
iFISH karyotype of meningiomas and the pattern of
infiltration of the tumor by inflammatory and other
immune cells
In order to better understand the molecular mechanisms that
could contribute to explain the association observed between the
pattern of infiltration of meningioma samples by inflammatory
cells and the tumor iFISH karyotype, we further investigated the
GEP of 40 meningioma samples using DNA oligonucleotide
arrays. Unsupervised hierarchical clustering analysis using those
79 genes, for which the highest variation among tumors with
distinct iFISH cytogenetic patterns was observed, showed clear
separation among meningioma samples displaying distinct karyo-
types, according to their mRNA expression profiles (Figure 6).
Analysis of the functional role of these 79 genes associated with the
different cytogenetic groups of meningiomas, showed that cases
with isolated monosomy 22/del(22q) were specifically character-
Figure 2. Distribution of tumor cells, inflammatory and other immune cells in meningioma samples classified according to the
cytogenetic profile of the tumor. Percentage of tumor cells (panel A), tissue macrophages (TiMa) (panel B) and total lymphocytes infiltrating
meningioma samples (panel C), grouped according to the cytogenetic iFISH profile of the tumor, are shown, as also the ratio between the number of
tumor cells and all other infiltrating cells (panel D). Notched-boxes represent 25th and 75th percentile values; the lines in the middle and vertical lines
correspond to median values and the 10th and 90th percentiles, respectively.
doi:10.1371/journal.pone.0074798.g002
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Figure 3. Immunophenotype of Tissue macrophages (TiMa) infiltrating meningioma samples, according to the cytogenetic profile
of tumor cells. The percentage of TiMa expressing CD69 (panel A), CD63 (panel B), CD16 (panel C) and CD33 (panel D) are shown together with the
mean amount of CD44 (panel E) and CD9 (panel F) expressed per TiMa infiltrating meningioma samples, according to the iFISH profile of tumor cells.
MFI, mean fluorescence intensity (arbitrary fluorescence units) per cell. Notched-boxes represent 25th and 75th percentile values; the lines in the
middle and vertical lines correspond to median values and the 10th and 90th percentiles, respectively.
doi:10.1371/journal.pone.0074798.g003
Figure 4. Distribution of the major lymphocyte subsets and activated CD69+ lymphocytes in inflammatory infiltrates of
meningiomas classified according to the cytogenetic profile of tumor cells. The percentage of total CD3+ T cells (panel A), CD3+ CD82 T
cells (panel B), CD3+ CD8+ T cells (panel C), activated CD69+ lymphocytes (panel D), CD32 CD192 56+ NK cells (panel E) and CD32 CD19+ B cells (panel
F) are shown. Notched-boxes represent 25th and 75th percentile values; the lines in the middle and vertical lines correspond to median values and the
10th and 90th percentiles, respectively.
doi:10.1371/journal.pone.0074798.g004
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Figure 5. Hierarchical clustering analysis of meningioma samples based on the relative distribution and the activation-associated
(CD69+) immunophenotypic profile of infiltrating inflammatory cells and lymphocytes: relationship with the cytogenetic
subgroups of the disease. Results are presented in a matrix format where each column represents a single immunophenotypic variable and
Inflammatory Infiltrates in Meningiomas
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ized by an increased expression of a set of genes which are related
to the inflammatory response and to signaling/activation of
immune cells. Among other genes, these included the BCL2,
C3AR1, CD37, CLEC7A, ELN, HLA-DMA, HOXC4, ITGAM,
LTBP2, MYO1F, PIK3CD, PLCB1 and TLR2 genes (Figure 6).
Conversely, diploid tumors were mainly characterized by overex-
pression of a group of genes, (e.g. ABCB1, ADSL, CHKB, PACSIN2,
PMM1 and TCN2 genes) which are mainly involved in small
molecule metabolism and cellular biochemistry, including also the
NF2 gene. Finally, tumors with complex karyotypes were
characterized by a greater expression of the ALDOA, TRA1,
NME1, NPLOC4 and TMED9 genes, as well as by decreased levels
of the ALPL, COL8A2, EFS, GSTM1, GSTM5, KCNMA1, KNS2,
LEPR, LPHN2, LTBP1, MAP3K5, PACS2, SFRP1, TIMP3 and
ZFYVE21 genes, most of such genes being mainly involved in
cellular functions related to cell death, cell cycle, cell growth and
proliferation, and to cellular assembly.
A more detailed functional analysis of the specific inflammatory
pathways involved in meningiomas with isolated monosomy 22/
del(22q) (IPA software) showed involvement of inflammatory
response genes which are specifically associated with immune
responses, cell adhesion, motility and activation and recruitment of
antigen presenting cells and/or macrophages (Figure 7). Altered
genes included HLA and HLA-associated molecules (HLA-DMA,
HLA-DMB, HLA-DRA, HLA-DRB1, HLA-DQA1, HLA-DQB and
CD74), inflammatory cytokines (IL16, IL1B, IL1R1, IL10RA,
IL11RA and IL17RA), complement proteins (C5, C3, C3AR1 and
C5AR1), immunoglobulin Fc (FcIg) receptors (FCGR1A, FCGR2A,
FCGR3B and FCER1G) and the CCR1 chemokine receptor,
integrins (ITGAM, ITGAX, ITGA4 and ITGB2) and other adhesion
molecules (VCAM1, CD53, CD58, CD81 and CD93), immune co-
stimulatory molecules (CD4, CD40 and CD86), toll-like receptors
(TLR2, TLR5 and TLR7) and TLR-associated molecules (CD14
and MYD88), growth factors and growth factor receptors (CSF1,
CSF1R and IGF1), apoptosis-associated proteins (BCL2 and BID),
together with phosphoinositide-3-kinases (PIK3CG and PIK3CD)
and other kinases (PRKCD, SYK, LYN and HCK), tyrosine
phosphatases (PTPRC and PTPN6), and signaling molecules
(CD69, CYBB, GAB2, HIF1A, INPP5D, IRF8, MSR1, SEMA4D,
TREM2, TYROBP and WAS) (Figure 7).
Noteworthy, a significant correlation was observed in those 13
meningioma samples in which GEP and flow cytometry immu-
nophenotyping were performed in parallel, for the percentage of
inflammatory and other immune cells infiltrating the tumor and
the mRNA levels of proteins specifically expressed by these cells
(e.g. TiMa) such as HLA-DR (r2 = 0.8; p,0.001), CD14 (r2 = 0.8;
p,0.001), Cybcl2 (r2 = 0.7; p = 0.01), CD53 (r2 = 0.7; p = 0.01),
CD37 (r2 = 0.7; p = 0.01), CD99 (r2 = 0.6; p = 0.02), CD45
(r2 = 0.6; p = 0.03), CD16 (r2 = 0.6; p = 0.04), CyD68 (r2 = 0.6;
p = 0.04), and HLA-I (r2 = 0.6; p = 0.04).
Discussion
According to the World Health Organization, meningiomas are
mostly classified as grade I benign tumors [2]; however, grade I
meningiomas are genetically very heterogeneous [6]. Accordingly,
distinct cytogenetic profiles have been identified in meningiomas,
which include (i) diploid tumors, (ii) tumors showing isolated
monosomy 22/del(22q), (iii) del(1p36) alone, (iii) isolated loss of a
sex chromosome, and (iv) meningiomas with complex karyotypes
in the absence or (v) presence of del(1p36) and/or monosomy 14.
From the prognostic point of view, meningiomas which have
complex karyotypes, particularly those carrying del(1p36) and/or
monosomy 14, display a significantly worse outcome, whereas
diploid tumors and cases with isolated monosomy 22/del(22q)
have a particularly good prognosis [6], as confirmed also in our
series.
At present, the specific factors that contribute to the better
outcome of 222/22q2 cases remain to be elucidated. Previous
studies have claimed that monosomy 22/del(22q) is frequently
associated with NF2 mutation, the later potentially representing
the first chromosomal alteration to occur in meningiomas; if this
hypothesis holds true, cases carrying an isolated loss of chromo-
some 22 could represent the earliest stage of neoplastic transfor-
mation in meningiomas [2]. However, more recent studies in
which the intratumoral patterns of cytogenetic evolution have
been analyzed in detail indicate that this is probably not the case;
more likely, loss of chromosome 22/NF2 mutation representing
one of multiple pathways of intratumoral clonal evolution
occurring in benign grade I meningiomas [7]. In line with this
hypothesis, Clark et al. have recently reported distinct genome
profiles of meningiomas based on the presence versus absence of
NF2 mutations, non-NF2 mutated meningiomas frequently show-
ing mutations in other genes (e.g. TRAF7, KLF4, AKT1 and SMO)
[20].
In turn, it should be taken into account that tumor behavior
depends not only on tumor cytogenetics, but also on the tumor
microenvironment, including surrounding cells which may either
support tumor growth or control the disease [21]. In this regard,
the potential role of immune cells infiltrating the tumor has
become particularly relevant, as the presence of inflammatory and
both cytotoxic and regulatory cells has been correlated with the
behavior of the disease (e.g. patient outcome) in multiple different
tumor types [11]. In the present study, we show a clear association
between the levels of immune/inflammatory cells infiltrating
meningiomas and tumor cytogenetics. Tumor infiltration by
immune/inflammatory cells had already been shown to be
associated in meningiomas with both tumor grade and the
histopathological subtypes [9,13]. By contrast, to the best of our
knowledge, this is the first report which shows a clear relationship
between inflammatory/immune infiltrates and tumor cytogenetics
in meningiomas. Overall, meningiomas carrying isolated mono-
somy 22/del(22q) showed significantly greater numbers of TiMa
infiltrating the tumor, together with a more pronounced activation
profile of immune cells, as reflected by greater percentages of
CD69+ and CD63+ TiMa and/or lymphocytes [22,23], versus
cases with either a diploid or a complex iFISH karyotype. In
addition, HLA-DR+CD14+CD45+CD68+ TiMa from patients
with isolated monosomy 22/del(22q) also showed higher levels of
expression of CD16, an FccRIII receptor typically absent in
recently produced blood monocytes, but expressed during
macrophage maturation in peripheral tissues (e.g. alveolar and
pleural macrophages) [24,25]. From a functional point of view,
each row corresponds to a different meningioma sample (rows annotated as ‘D’, ‘222’ and ‘C’ correspond to meningiomas with diploid, isolated
monosomy 22/del(22q) and complex iFISH karyotypes, respectively). Normalized values are represented by a color scale where red and green colors
reflect values above and below the mean values obtained for each variable, respectively (panel A). A 3-dimensional principal component analysis
(PCA) representation of all meningioma samples based on the number and features of inflammatory cells and lymphocytes infiltrating the tumor, as
analyzed by flow cytometry (n = 51) is displayed; as shown there, most tumors with isolated monosomy 22/del(22q) (orange dots) tend to cluster
together based on the pattern of infiltration of the tumor by inflammatory and other immune cells (panel B).
doi:10.1371/journal.pone.0074798.g005
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expression of CD16 enables macrophages to carry out antibody-
dependent cell-mediated cytotoxic functions, which would make
them more efficient phagocytic cells [26]. Altogether, these results
suggest that in addition to the greater numbers of TiMa infiltrating
the tumor, TiMa from meningiomas carrying monosomy 22/
del(22q) alone would also show a more activated and functionally
matured phenotype. In this regard, TiMa of both 222/22q2 and
cytogenetically complex meningiomas also showed higher expres-
sion of both the CD44 and CD9 adhesion molecules vs diploid
cases. CD44 is a cell-adhesion molecule which is expressed by
macrophages [27], and has been previously reported to be up-
regulated in tumor-associated macrophages, playing a role in their
recruitment and activation [28,29]. Similarly, the CD9 tetraspanin
has also been reported to promote activation of macrophages
through its functional association with Fcc receptors [30]. These
observations further support a central role for TiMa in controlling
tumor growth, as well as in promoting homing/chemoattraction of
inflammatory and other immune cells to the tumor, among
meningiomas with isolated monosomy 22/del(22q), which could
potentially contribute to explain the better outcome of this specific
subgroup of meningioma patients vs cases with complex karyo-
types.
In line with this hypothesis, meningiomas with isolated
monosomy 22/del(22q) also displayed a greater infiltration by
NK cells and lymphocytes expressing the CD69 early-activation
antigen. Although NK cells and CD69+ activated lymphocytes
only represented a small fraction of all infiltrating cells they may
also contribute to immune surveillance and to the elimination of
Figure 6. Hierarchical clustering analysis of the GEP of meningioma samples. Results are presented in a GEP matrix format where each row
represents a single gene (listed with the corresponding gene symbol) and each column corresponds to a distinct meningioma sample (n = 40); those
columns identified as ‘D’ (colored yellow), ‘222’ (colored orange) and ‘C’ (blue color) correspond to individual meningioma tumors with a diploid,
monosomy 22/del(22q) and complex iFISH karyotype, respectively. Normalized values are represented by a color scale where red and green colors
indicate values above and below the mean mRNA expression values, respectively. Hierarchical clustering analysis was based on the expression of
those 79 genes which showed the highest classification power for the three cytogenetic subgroups of meningiomas. On the right side of the plot, the
major common functions of the listed genes, based on the analyses performed with the Ingenuity Pathway software, are indicated. As displayed,
genes overexpressed in meningiomas carrying monosomy 22/del(22q) are mainly involved in inflammatory cell functions.
doi:10.1371/journal.pone.0074798.g006
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tumor cells and thus, to control tumor growth through direct
cytotoxic mechanisms cooperating with those of tissue macro-
phages [31].
To further investigate the molecular mechanisms involved in
inflammatory and immune responses in those tumors carrying
isolated monosomy 22/del(22q) vs other meningiomas, we further
analyzed the GEP of tumor samples from the distinct cytogenetic
subgroups of meningiomas. As expected, meningiomas with
isolated monosomy 22/del(22q) typically showed a GEP associated
with an increased inflammatory and immune response consisting
of greater expression of genes involved in antigen presentation (e.g.
HLA and HLA-associated molecules), phagocytosis (Fc receptors)
and cell activation/cell signaling (e.g. immune co-stimulatory
molecules, toll-like receptors and inflammatory cytokines), when
compared to tumors with diploid and complex karyotypes.
So far, two distinct populations of functionally polarized
macrophages have been described, which are generated depend-
ing on the cytokines present in the tissue microenvironment:
classical M1 macrophage which develop under the influence of
LPS and IFN-c, produce pro-inflammatory cytokines (e.g. IL-12,
IL-1, and IL-6), mediate resistance to pathogens and contribute to
tissue destruction, and; M2 macrophages, developed under the
influence of IL-4 and IL-10, which produce anti-inflammatory
cytokines (e.g. IL-10 and TGF-b), promote tissue repair and
remodeling and support to tumor progression [32]. Despite
lacking specific markers, M1 macrophages express receptors like
CD16, CD32, CD64 and CD86, while M2 macrophages are
characterized by abundant levels of CD163 and CD206. Although
until now there is no information about the type of macrophages
that infiltrate meningiomas, the higher expression levels of CD16
(FCGR3A) found here both at the protein and mRNA levels,
together with the increased mRNA levels of CD86, CD32
(FCGR2A) and CD64 (FCGR1A) observed in meningiomas with
monosomy 22/del(22q) alone, support an M1 vs M2 polarization
of macrophages in this subgroup of meningiomas and conse-
quently also, a more favorable anti-tumoral microenvironment. In
Figure 7. Schematic representation of the functional impact of GEP of meningiomas with isolated monosomy 22/del(22q). The
scheme was built based on the results obtained through the analysis of GEP performed with the Ingenuity Pathway Analysis software and it shows
increased expression of several inflammatory genes, particularly genes involved in antigen presenting cell functions, among cases with isolated
monosomy 22/del(22q). Such genes include HLA and HLA-associated molecules (HLA-DMA, HLA-DMB, HLA-DRA, HLA-DRB1, HLA-DQA1, HLA-DQB and
CD74), cytokines (IL16, IL1B, IL1R1, IL10RA, IL11RA and IL17RA), growth factors and growth factor receptors (CSF1, CSF1R, IGF1, IGF2R, VEGF and
PDGFRB), complement proteins (C5, C3, C3AR1, C5AR1 and CD59), immunoglobulin Fc (FcIg) receptors (FCGR1A, FCGR2A, FCGR3B and FCER1G) and the
CCR1 chemokine receptor, integrins (ITGAM, ITGAX, ITGA4 and ITGB2) and other adhesion molecules (VCAM1, CD44, CD53, CD58, CD81 and CD93),
immune co-stimulatory molecules (CD4, CD40 and CD86), toll-like receptors (TLR2, TLR5 and TLR7) and TLR-associated molecules (CD14 and MYD88),
together with phosphoinositide-3-kinases (PIK3CG and PIK3CD) and other kinases (PRKCA, PRKCD, SYK, LYN and HCK), tyrosine phosphatases (PTPRC
and PTPN6), and apoptotic proteins (BCL2 and BID), together with other signaling molecules (CD69, CYBB, GAB2, HIF1A, INPP5D, IRF5, IRF8, MIF, MSR1,
SEMA4D, TREM2, TYROBP and WAS).
doi:10.1371/journal.pone.0074798.g007
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line with this, NK cells have been reported to play an indirect role
in redirecting macrophage activation toward the M1 phenotype
[32,33], NK cells being also found at higher numbers in our series
of meningiomas with an isolated 222/22q2 karyotype. Similarly,
higher levels of expression of IRF5 and IRF8, but not IRF4, were
reported as part of the GEP characteristic of 222/22q2
meningiomas; while IRF5 production has been shown to play a
critical role in M1 macrophage polarization [34], IRF4 stimulates
expression of M2 macrophage markers [35]. Altogether these
results support a predominant M1 polarization of macrophages in
meningiomas with isolated monosomy 22/del(22q) and potentially
also their better prognosis versus other cytogenetic subtypes of
meningiomas (e.g. cases with complex karyotypes). Further
investigations about the functional behavior of infiltrating macro-
phages in meningiomas are needed to confirm this hypothesis.
Whether or not the inflammatory responses in meningiomas are
directly determined by the loss of expression in tumor cells of genes
specifically coded in chromosome 22/22q, also deserves further
investigation. Despite this, it should be noted that the most
significant immune response-associated gene coded in chromo-
some 22, which was lost in this cytogenetic subgroup of
meningiomas, is the MIF gene. MIF was originally identified as
a T-cell-derived factor responsible for the inhibition of macro-
phage migration [36]. However, nowadays MIF has been
recognized to act as a pro-inflammatory cytokine which is both
involved in inflammatory and immune responses, as well as in
tumor cell growth and invasiveness [36,37]. In this regard, recent
studies indicate that MIF protein levels are elevated in cancer
patients [37,38] and that MIF expression directly correlates with
stage, metastatic spread, disease-free survival and tumor-associated
neovascularization in e.g. lung, prostate, breast and gastric cancer,
as well as glioma patients [37,39,40,41,42,43]. Thus, loss of MIF
in meningiomas with isolated monosomy 22/del(22q) may also
play an important role in determining the more indolent behavior
and the good prognosis of this subgroup of meningioma patients.
In summary, our results indicate that an increased infiltration of
the tumor by tissue macrophages, NK cells and activated
lymphocytes in meningiomas, is specifically associated with cases
carrying an isolate monosomy 22/del(22q). Whether such
enhanced inflammatory/immune infiltrates is due to the loss of
expression of specific genes coded in chromosome 22 and whether
it reflects an increased anti-tumoral response contributing to
disease control and the better outcome of these patients, deserves
further investigations.
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